Hao Oubo announcement, according to the latest company's P/E ratio released by China Securities Index Co., Ltd., the latest trailing P/E ratio is 142.62 times, and the average trailing P/E ratio of the pharmaceutical manufacturing industry where the company is located in the last month is 26.96 times. The company's P/E ratio is significantly higher than the industry average. The matter of the company's controlling shareholder, Hairui Xiangtian, transferring the shares to Brilliant Runkang has been approved by the board of directors of Sino Biopharm, the actual controlling shareholder of Brilliant Runkang and Shuangrun An; the "Share Transfer Agreement" involved in this transaction has been internally decided and signed by the contracting parties, and is awaiting approval by the company's shareholders' meeting to exempt JOHN LI from fulfilling voluntary share lock-up commitments and to approve the effectiveness of the strategic cooperation between the company and Sino Biopharm, Hairui Xiangtian, and JOHN LI; after the "Share Transfer Agreement" takes effect, it also needs to obtain the compliance confirmation opinion from the Shanghai Stock Exchange and other approvals that may be required by relevant laws and regulations before the share transfer registration procedures can be handled at the Shanghai Branch of China Securities Depository and Clearing Corporation Limited. There is a certain degree of uncertainty regarding whether the related approval procedures can be passed and the time of passage.